As our in vitro data suggest that the therapy of breast cancer, and more specifically of TNBCs, the most aggressive subtype of breast cancer, may benefit from the antitumor activity of DDX3X inhibitors, we next set up to study the efficacy of FHP01 treatment in vivo, in a TNBC mouse model. Here, DDX3X is linked to breast carcinoma.